Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This phase Ib trial studies the side effects and best dose of isatuximab when given together
with carfilzomib with or without dexamethasone and lenalidomide in treating patients with
multiple myeloma that has returned after a period of improvement (relapsed) or has not
respond to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as
isatuximab, may induce changes in the body's immune system and may interfere with the ability
of tumor cells to grow and spread. Carfilzomib may stop the growth of cancer cells by
blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as
dexamethasone and lenalidomide, work in different ways to stop the growth of cancer cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving isatuximab and carfilzomib with or without dexamethasone and lenalidomide
may be a better treatment for patients with multiple myeloma.
Phase:
Phase 1
Details
Lead Sponsor:
Thomas Martin, MD University of California, San Francisco